Literature DB >> 2295816

Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis.

R Jänicke1, D N Männel.   

Abstract

Several lines of evidence point to an activation mechanism of monocytes/macrophages by tumor cells. In this study we present data for distinct surface structures on K562 and Jurkat cells to directly induce TNF-mRNA expression and TNF production by human peripheral blood monocytes. Northern analysis showed that incubation of monocytes with either K562 or Jurkat cells led to a significant increase in TNF-mRNA expression. In addition, enhanced TNF production was detected in supernatants of monocyte cultures activated by Jurkat cells. Not only viable tumor cells but also metabolically inactivated tumor cells, cytoblasts, and membrane preparations from Jurkat and K562 cells induced TNF-mRNA expression. We identified two different membrane protein fractions with relative molecular mass of 32 to 38 kDa for Jurkat cells and 46 to 54 kDa for K562 cells that were responsible for monocyte activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295816

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Differential effects of human blood monocytes on the growth of human tumour cell lines in vitro.

Authors:  H J Parry; R C Rees
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 2.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

3.  Role of interferon gamma and tumour necrosis factor alpha in monocyte-mediated cytostasis and cytotoxicity against a human histiocytic lymphoma cell line.

Authors:  A A van de Loosdrecht; G J Ossenkoppele; R H Beelen; M G Broekhoven; M M Langenhuijsen
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Monocyte activation in patients with non-seminomatous germ cell tumour of the testis before and after tumour eradication.

Authors:  A Trulson; S Nilsson; P Venge
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

5.  Phenotypic analyses of lymphokine-activated killer cells that release interferon gamma and tumor necrosis factor alpha.

Authors:  A S Chong; B Ybarrondo; W J Grimes; E M Hersh; P Scuderi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Early differential molecular response of a macrophage cell line to yeast and hyphal forms of Candida albicans.

Authors:  E Blasi; L Pitzurra; M Puliti; L Lanfrancone; F Bistoni
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

7.  Isoniazid protects mice against endotoxin lethality without influencing tumor necrosis factor synthesis and release.

Authors:  R Urbaschek; D N Männel; R Urbanczik
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

8.  Tumour-cell-induced production of tumour necrosis factor by monocytes of gastric cancer patients receiving BCG immunotherapy.

Authors:  M Zembala; A Czupryna; J Wieckiewicz; M Jasinski; J Pryjma; I Ruggiero; M Siedlar; T Popiela
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Inflammation amplifies the antitumor cytostasis by human peritoneal macrophages.

Authors:  S Ben-Efraim; C Tak; M J Fieren; G J Van den Bemd; I L Bonta
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

10.  Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer.

Authors:  O Gallo; A M Gori; M Attanasio; F Martini; B Giusti; M Boddi; E Gallina; O Fini; R Abbate
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.